Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Christopher Spencer Winter has worked on the following 33 EPO patent applications which have been published in the last five years:

EP13182099

Engineered Fc regions for site-specific conjugation

IPC classification:
A61K 39/00, A61K 47/48, C07K 16/00, C12P 21/08
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP11841807

COMBINATION THERAPY FOR B CELL LYMPHOMAS

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/28
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13168817

Methods of treating systemic lupus erythematosus

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12196199

Antibodies with decreased deamidation profiles

IPC classification:
A61K 9/00, A61K 39/395, A61K 47/02, A61K 47/12, A61K 47/18, A61K 47/26, C07K 16/24
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12756712

ANTI-SIGLEC-15 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Cambridge Enterprise Ltd.
Applicant:
MedImmune Limited
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP12848121

MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF

IPC classification:
A61K 39/00
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP14169713

Optimized degenerative muscle disease diagnostics and treatments

IPC classification:
A61K 31/56, A61K 31/7088, A61K 35/34, A61K 39/00, A61K 39/395, A61K 45/00, C12Q 1/00, C12Q 1/68, G01N 33/48, G01N 33/53, G01N 33/68
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13758582

METHODS OF TREATMENT WITH ANGIOPOIETIN-2 ANTIBODIES

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/00
Applicant:
MedImmune, LLC
Applicant:
University of Helsinki (Helsingin yliopisto)
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP13784604

MOLECULES WITH REDUCED EFFECTOR FUNCTION AND EXTENDED HALF-LIVES, COMPOSITIONS, AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/00, C12P 21/08
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP13803921

FIXED DOSAGE REGIMENS FOR ANTI-TYPE I INTERFERON RECEPTOR (IFNAR) ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP11769481

TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS

IPC classification:
A61K 39/00, A61K 39/395, C07K 14/00, C07K 14/78, C07K 16/10, C07K 16/28, C07K 16/46, C07K 19/00
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP13805277

ANTIBODIES TO AMYLOID BETA

IPC classification:
C07K 16/18
Applicant:
MedImmune Limited
Agent:
Diana Jean Pisani, Ropes & Gray International LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP14186905

Anti-ILT7 antibody

IPC classification:
A61K 39/00, A61K 39/395, A61P 37/00, C07K 16/28, G01N 33/566, G01N 33/577, G01N 33/68
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP13853844

METHODS OF TREATING S. AUREUS-ASSOCIATED DISEASES

IPC classification:
A61K 39/085
Applicant:
MedImmune, LLC
Agent:
Multiple attorneys, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP11755347

CHINESE HAMSTER OVARY CELL LINE

IPC classification:
C12N 5/16
Applicant:
MedImmune Limited
Agent:
Multiple attorneys, MedImmune Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14766962

ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30
Applicant:
MedImmune Limited
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION IN PROGRESS
EP11761051

FACTOR II ALONE OR IN COMBIATION WITH FURTHER FACTORS FOR TREATMENT OF IMPAIRED HAEMOSTASIS ASSOCIATED WITH DILUTIONAL COAGULOPATHY

IPC classification:
A61K 38/36, A61K 38/48, A61P 7/04
Applicant:
MedImmune Limited
Agent:
Multiple attorneys, MedImmune Limited
Status:
PATENT GRANTED
EP14850550

NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF

IPC classification:
A61P 31/16
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
GRANT OF PATENT INTENDED
EP11741602

MONOMERIC POLYPEPTIDES COMPRISING VARIANT FC REGIONS AND METHODS OF USE

IPC classification:
C07K 16/28
Applicant:
MedImmune Limited
Agent:
Multiple attorneys, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11817285

DETECTION OF LCAT ACTIVITY

IPC classification:
C12Q 1/48
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11858565

HSA-RELATED COMPOSITIONS AND METHODS OF USE

IPC classification:
A61K 38/38, A61K 47/48, C07K 14/765
Applicant:
MedImmune, LLC
Agent:
Thomas Zvesper, Mathys & Squire LLP
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14856296

ANTIBODY PURIFICATION

IPC classification:
B01D 15/08, C07K 16/00, C07K 16/18
Applicant:
MedImmune, LLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15769523

SINGLE-USE, SELF DESTRUCTING SHIELD FOR SYRINGE NEEDLE

IPC classification:
A61M 5/32
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15777039

CONJUGATED COMPOUNDS COMPRISING CYSTEINE-ENGINEERED ANTIBODIES

IPC classification:
C07K 16/30
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15777523

TUBULYSIN DERIVATIVES

IPC classification:
A61K 31/426, A61K 31/427, C07D 277/30
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15788683

METHODS OF USING ANTI-ANG2 ANTIBODIES

IPC classification:
A61K 39/395
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15722195

ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
MedImmune Limited
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15727571

TREATMENT FOR RHEUMATOID ARTHRITIS

IPC classification:
A61K 39/00, A61K 39/395, C07K 16/28
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15726122

ANTAGONISTS OF PDL-1 AND PD-1 FOR THE TREATMENT OF HPV-NEGATIVE CANCERS

IPC classification:
A61K 39/00, C07K 16/28, C07K 16/30
Applicant:
MedImmune Limited
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP16199226

COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/22, C07K 16/28
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
EXAMINATION REQUESTED
EP15763528

METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY USING MARKERS (CXCL9, KRT8.TRIM29, AND IFNGAMMA)

IPC classification:
A61K 39/00, A61P 35/00, C07K 14/47, C07K 14/52, C07K 16/28, C12Q 1/68, G01N 33/574
Applicant:
MedImmune Limited
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
Request for examination was made
EP15782151

METHOD OF CONJUGATING A POLYPEPTIDE

IPC classification:
A61K 47/50
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
Request for examination was made
EP15848683

HUMANIZED ANTI-OX40 ANTIBODIES AND USES THEREOF

IPC classification:
A61K 39/395, C07K 16/28
Agent:
AstraZeneca PLC
Agent:
Christopher Spencer Winter, MedImmune Limited
Status:
Request for examination was made

Please Sign in to use this feature